Table 2.

Comparison by treatment group of mean UPDRS Part II and Part III scores before and after treatment.

	UPDRS II		UPDRS III
	(Activities of daily living)		(Motor examination)
	NC001	Placebo	NC001	Placebo
LS means ± SE*
Baseline	13.1 ± 6.0	11.4 ± 5.3	20.0 ± 8.8	16.9 ± 8.3
Week 10	10.1 ± 5.3	8.8 ± 5.0	17.3 ± 10.6	16.8 ± 8.6
Change	2.8 ± 5.2	2.7 ± 4.5	2.0 ± 7.5	−0.4 ± 6.5
NC001 vs. placebo†
Difference in LS means ± SE (95% CI)	10.1 ± 0.96 (6.9–12.1)		−18.3 ± 1.8 (−24.1 to −16.3)
P-value	0.63		0.34

^*At baseline, n = 35 NC001 patients and n = 30 placebo patients. At 10 weeks, n = 30 NC001 patients and n = 27 placebo patients.

^†Comparison of baseline to week 10. LS, least squares; UPDRS, Unified Parkinson's Disease Rating Scale.